Company intelligence / Profile preview
VALANX Biotech
Graz, Austriavalanx.bio ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Preclinical
01
Overview
VALANX Biotech’s lead candidate, VLX101, a novel Interleukin‑2 conjugate developed with their proprietary site-specific protein conjugation platform, demonstrated promising preclinical efficacy in autoimmune disease models. The company’s approach enables precise half-life extension without the drawbacks of PEGylation. No clinical data yet; first-in-human studies are planned.
- Therapeutic areas
- Immunology
- Modalities
- ProteinProtein-drug conjugateRecombinant proteinSynthetic amino acid-based conjugates (platform)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Fina Biosolutions/FinaBio – partnership to develop ClickCRM for rapid vaccine development using VALANX's platform technology
Beyond the preview
Go deeper on VALANX Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VALANX Biotech.